Resource
Dear Reader:
A Message from the President
Scientific & Clinical
IMF's International Myeloma Working Group; The Annual IMWG Summit
The Role of Protein Electrophoresis Testing in Myeloma - Myeloma…
Resource
Patients with myeloma are surviving longer and, therefore, may experience continuing effects of their disease and treatment. Through clinical experience, the International Myeloma Foundation Nurse Leadership Board (NLB) was aware that a specific set of needs exists in this patient population.…
Resource
Dear Reader
A Message from the President
Scientific & Clinical
Myeloma Today in Conversation with C. Ola Landgren, MD, PhD
The Current Role of Serum Free Light Chain Analysis in Myeloma - Myeloma Today in…
Resource
Dear Reader:
Looking back over the last 20 years.
Board of Directors: The IMF Board of Directors welcomes its newly elected members
Donna Feig
John A. O'Dwyer
Dr. S. Vincent Rajkumar
…
Resource
As novel agents are being more commonly used for the treatment of multiple myeloma, the role of high-dose therapy followed by autologous stem cell transplantation (ASCT) continues to evolve. Induction therapy is no longer just conventional chemotherapy regimens. Rather, induction therapy now uses “…
Resource
This 2010 Myeloma Today, a multiple myeloma cancer journal, is a Special Gala Report, covering the IMF’s 4th Annual Comedy Celebration.
Click here to download Myeloma Today
Resource
This study sought to “identify genetic variation that can modulate and predict the risk of developing thalidomide-related peripheral neuropathy (TrPN).” Analyzed were 1,495 patients with multiple myeloma. The clinicians learned that “an individual’s risk of developing a peripheral neuropathy after…
Resource
Many cancer patients who undergo chemotherapy experience peripheral neuropathy, which is characterized by numbness, tingling, and/or pain in the hands, feet, legs, and/or arms. In fact, almost every effective regimen for the treatment of multiple myeloma “includes at least one agent that can cause…
Resource
Dear Reader
A Message from the President
Scientific & Clinical
The Current Role of Transplantation in Multiple Myeloma: Myeloma Today in conversation with Dr. Cristina Gasparetto
Bone Disease in Multiple…
Resource
Dear Reader
A Message from the President
News and Notes
Obesity and risk of MGUS
MGUS and risk of skeletal fractures
Myeloma-associated chromosomal abnormalities
Arterial thrombosis in…
Resource
This analysis focuses on comparing both early onset and late onset bortezomib-induced peripheral neuropathy to vincristine-induced peripheral neuropathy. When a myeloma patient has dose-limiting based toxicity due to bortezomib, bortezomib-induced peripheral neuropathy may result, negatively…
Resource
Renal impairment is a common complication of multiple myeloma (MM). The estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula is the recommended method for the assessment of renal function in patients…
Resource
This report from the International Myeloma Working Group (IMWG) focuses on the multiple myeloma (MM) and its complication of lytic bone disease. Lytic bone disease is a disease that destroys the bone and can rarely be reversed. To observe lytic bone disease’s impact, “biochemical markers of bone…
Resource
This statement concludes that treating multiple myeloma (MM) patients with allogeneic stem-cell transplantation (Allo-SCT) is not more successful than autologous stem-cell transplantation. In addition, more guidelines are needed to be set in order to make Allo-SCT a better form of treatment.…
Resource
The intent of this statement is to provide a biological classification of multiple myeloma and to establish the prognostic value of known genetic factors.
Myeloma is divided at the highest genetic level into two subtypes: disease that is hyperdiploid (h-MM), and disease that is non-hyperdiploid…
Resource
For the more than 3% of myeloma patients who have non-secretory or oligosecretory disease, and for the majority of patients with AL amyloidosis (AL), the traditional methods of measuring circulating monoclonal immunoglobulins (electrophoresis, immunoelectrophoresis, immunofixation electrophoresis,…
Resource
Dear Reader
A Message from the President
Scientific & Clinical
Cure versus Control: Myeloma Today in conversation with Dr. S. Vincent Rajkumar
Induction Therapy Prior to Autologous Stem Cell…
Resource
Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21,463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom’s macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is…
Resource
The International Myeloma Working Group [(MWG) has established response criteria for myeloma. This criteria has been accepted by the myeloma community, the Food and Drug Administration (FDA), and the broader medical establishment.
Myeloma is unique, in that a majority of patients can be…
Resource
The risk of VTE in cancer patients is greater than 7%; those with myeloma have the highest risk of thrombosis.2 The oral immunomodulatory drugs, thalidomide and lenalidomide, further increase that risk. The following guidelines from the International Myeloma Working Group recommend a prophylaxis…
Resource
Dear Reader
A Message from the President
IMF Welcomes Daniel Navid as Senior Global Analyst
Board of Directors
The IMF Welcomes Entertainment Industry Executive to Board of Directors; Myeloma…
Resource
The purpose of this study is to determine the correlation between age and survival, as well as how many years myeloma patients will lose due to their condition. In the study, 10,549 patients were studied, with 6,996 receiving conventional therapy, and 3,553 patients receiving high-dose therapy with…
Resource
Dear Reader: As 2009 draws to a close, the first question is "WHERE DID IT GO?!"
Scientific & Clinical: Studies Presented at ASH 2009 May Offer New Approaches to Treating Myeloma
Spotlight on Advocacy: ASH 2009 - IMF Advocacy…
Resource
Bone disease in myeloma occurs as a result of complex interactions between myeloma cells and the bone marrow microenvironment. A custom-built DNA single nucleotide polymorphism (SNP) chip containing 3404 SNPs was used to test genomic DNA from myeloma patients classified by the extent of bone…
Resource
The International Myeloma Working Group (IMWG) provides a statement on autologous stem cell support (ASCT). This statement explains how multiple myeloma calls for high-dose chemotherapy with ASCT most commonly in North America as of present. Generally, this is executed by collecting at least 2…
Resource
The goals of this paper are the following:
to biologically classify multiple myeloma “based on known genetic subtypes with associated clinico-pathological associations”
“to establish the prognostic value of known and new genetic factors for MM outcome, including the…
Resource
The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem cell transplantation remains an important…
Resource
Dear Reader
A Message from the President
Board of Directors
Myeloma Today in Conversation with Charles Newman
Scientific & Clinical
2009 Waldenström's Award; Dr…
Resource
This statement reviews imaging methods that can detect bone and soft tissue damage caused by multiple myeloma (MM), including the following:
Conventional radiography: “gold standard” in imaging studies of myeloma patients
Computed tomography (CT): When an MRI is not…
Resource
Dear Reader
Board of Directors: Myeloma Today in conversation with Edith Peterson Mitchell, MD, FACP
Scientific & Clinical: The Role of Zolinza® in Multiple Myeloma; Myeloma Today in conversation with Dr. David Siegel
Scientific…
Resource
When treating myeloma patients with thalidomide, there is a possible risk of venous thromboembolism that can follow with a risk of pulmonary embolism. “To test genetic variation associated with treatment related VTE in patient peripheral blood DNA,” this study uses a “custom-built molecular…
Resource
International Myeloma Working Group (IMWG) guidelines for serum free light chain analysis in multiple myeloma and related disorders
For the more than 3% of myeloma patients who have non-secretory or oligosecretory disease, and for the majority of patients with AL amyloidosis (AL…
Resource
This statement attempts to explain four aspects of myeloma:
20,000 new American patients are diagnosed every year
There are about 100,000 myeloma patients in America due to better forms of treatment that increase survival rates. This statistic is the same throughout Europe…
Resource
Dear Reader
Board of Directors: Myeloma Today in conversation with Loraine Boyle
Scientific Advisory Board: Myeloma Today in conversation with Dr. Sagar Lonial
News & Notes
Scientific & Clinical:…
Resource
Not much information has been obtained on multiple myeloma’s (MM) occurrence rates and treatments in Latin America. However, this analysis observes factors of MM in Brazil based on information provided by sixteen institutions. This study identified “the unique aspect of the pattern of the disease…
Resource
This analysis compares 1689 multiple myeloma patients under the age of 50 with 8860 patients at least 50 years old or older. Distinguishing factors from the younger group were that myeloma was more common among men, had a low International Staging System (ISS) stage, had a low Durie-Salmon stage,…
Resource
Dear Reader
Board of Directors: Myeloma Today in conversation with Mark DiCicilia
Scientific Advisory Board: Myeloma Today in conversation with Dr. Alan Solomon
News & Notes
Scientific & Clinical: Europe…
Resource
This manuscript intends to explain prophylaxis strategies for venous thromboembolism (VTE). VTE is more common in cancer patients than in the general population, whose VTE occurrence is more than 1 in every thousand. In the context of multiple myeloma patients, their risk of VTE increases when…
Resource
Dear Reader
A Message from the President
Scientific & Clinical
New Findings Reported at ASH
2008 IMF Research Grant Recipients Announced
Serum Free Light Chain Testing for Diagnosis and Monitoring; MT in…
Resource
Dear Reader
A Message from the President
Scientific & Clinical
In Conversation with Dr. Antonio P. Palumbo
In Conversation with Dr. Robert A. Kyle…
Resource
Dear Reader
A Message from the President
Scientific & Clinical
HOVON: The Dutch-Belgian Hemato-Oncology Group - MT in conversation with Prof. Pieter Sonneveld
Updates from Recent…
Resource
Dear Reader
A Message from the President
Board of Directors Profile
A Conversation with Michael Katz
Scientific Advisor Profile
A Conversation with Prof. Meletios Dimopoulos…
Resource
This statement made by the International Myeloma Working Group (IMWG) responds to the Mayo Clinic’s statement on using bisphosphonates (BPs) on patients with multiple myeloma. The Mayo Clinic is usually in agreement with the IMWG. However, in this instance, the IMWG does not entirely agree with the…
Resource
Dear Reader
A Message from the President
Scientific & Clinical
Report from ASH: Read about some of the most significant myeloma-related news from the 48th annual meeting of the American Society of Hematology (ASH…
Resource
Dear Reader
A Message from the President
Scientific & Clinical
REVLIMID® Approved for Myeloma
Summary of New International Uniform Response Criteria for…
Resource
The methods to consider when analyzing the outcomes of myeloma clinical trials have been expanded in the European Group for Blood and Bone Marrow Transplant/ International Bone Marrow Transplant Registry. This revised form of International Response Criteria may possibly be widely used in future…
Resource
Dear Reader
A Message from the President
Scientific & Clinical
The 2006 IMF Scientific Board Retreat
The 2006 Annual Meeting of the American Society of Clinical Oncology
The IMF Symposium at…
Resource
Focus on Myeloma and Plasma Cell Disorders; Conference Overview with Morton Coleman, MD
Update on the Role of Lenalidomide (Revlimid®) in Myeloma
The Role of Bortezomib in Previously Untreated Myeloma
…
Resource
Dear Reader
A Message from the President
Scientific & Clinical
American Society of Hematology 47th Annual Meeting
2006 IMF Brian D. Novis Research Grant Awards
CDC Grant Award Update…
Resource
Dear Reader
A Message from the President
Scientific & Clinical
Pathogenisis and Maintenance of Multiple Myeloma
Making Clinical Trials More Patient-Friendly
MOZOBIL, a Potential New Agent for Stem Cell Harvesting…